Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Market Value Added (MVA)

Microsoft Excel

MVA

Celgene Corp., MVA calculation

US$ in millions

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Fair value of debt1 19,300 16,600 14,572 14,299 7,088
Operating lease liability 375 209 191 206 197
Market value of common equity 62,991 71,577 89,941 77,846 98,817
Preferred stock, $.01 par value per share; none outstanding
Less: Debt securities available-for-sale and equity investments with readily determinable fair values 1,808 5,029 1,800 1,672 3,425
Market (fair) value of Celgene 80,859 83,358 102,904 90,679 102,676
Less: Invested capital2 27,773 18,857 18,672 18,136 9,844
MVA 53,085 64,500 84,232 72,544 92,832

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Fair value of debt. See details »

2 Invested capital. See details »

Item Description The company
MVA Celgene Corp. market (fair) value less invested capital. Celgene Corp. MVA decreased from 2016 to 2017 and from 2017 to 2018.

MVA Spread Ratio

Celgene Corp., MVA spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Market value added (MVA)1 53,085 64,500 84,232 72,544 92,832
Invested capital2 27,773 18,857 18,672 18,136 9,844
Performance Ratio
MVA spread ratio3 191.14% 342.04% 451.11% 400.01% 943.04%
Benchmarks
MVA Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 MVA. See details »

2 Invested capital. See details »

3 2018 Calculation
MVA spread ratio = 100 × MVA ÷ Invested capital
= 100 × 53,085 ÷ 27,773 = 191.14%

4 Click competitor name to see calculations.

Performance ratio Description The company
MVA spread ratio The ratio of MVA to invested capital. It measures the efficiency with which investors’ capital investment has translated into a franchise value and into an aggregate net present value premium. Celgene Corp. MVA spread ratio deteriorated from 2016 to 2017 and from 2017 to 2018.

MVA Margin

Celgene Corp., MVA margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (US$ in millions)
Market value added (MVA)1 53,085 64,500 84,232 72,544 92,832
 
Net product sales 15,265 12,973 11,185 9,161 7,564
Add: Increase (decrease) in deferred revenue 37 26 (8) 34 5
Adjusted net product sales 15,302 12,999 11,177 9,195 7,569
Performance Ratio
MVA margin2 346.92% 496.19% 753.62% 788.91% 1,226.53%
Benchmarks
MVA Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 MVA. See details »

2 2018 Calculation
MVA margin = 100 × MVA ÷ Adjusted net product sales
= 100 × 53,085 ÷ 15,302 = 346.92%

3 Click competitor name to see calculations.

Performance ratio Description The company
MVA margin The ratio of MVA to sales. It measures how efficiently and prodigiously sales translate into franchise value. Celgene Corp. MVA margin ratio deteriorated from 2016 to 2017 and from 2017 to 2018.